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Abstract
The potential relationship between coronary artery calcium (CAC) and colorectal adenoma has been widely indicated. This study
aimed to investigate the relationship between the risk of colorectal adenoma and CAC progression in asymptomatic Korean adults
who underwent serial assessments by colonoscopy and CAC scan.
A total of 754 asymptomatic participants, who had undergone serial CAC scans and colonoscopies for screening, were enrolled.
Changes in CAC were assessed according to the absolute change between baseline and follow-up results. CAC progression was
deﬁned using Multi-Ethnic Study of Atherosclerosis method. Risk for adenoma at follow-up colonoscopy was determined using
hazard ratio (HR) by Cox regression. The area under the receiver operating characteristic (ROC) curve was measured.
The mean follow-up duration was 3.4 ± 2.5 years. CAC progression was found in 215 participants (28.5%). Participants with
adenoma at index colonoscopy showed a higher rate of CAC progression than those without (38.8% vs 23.6%, P< .01). In
participants with adenoma at index colonoscopy, CAC progression signiﬁcantly increased the cumulative risk for adenoma at follow-
up colonoscopy (HR=1.48, 95% conﬁdence interval [CI] 1.06–2.06, log-rank P= .021). In multivariate analysis, male sex (HR=2.57,
95% CI 1.22–5.42, P= .013), ≥3 adenomas at index colonoscopy (HR=2.60, 95% CI 1.16–5.85, P= .021), and CAC progression
(HR=2.74, 95%CI 1.48–5.08, P= .001) increased the risk of adenoma at follow-up colonoscopy. In participants without adenoma at
index colonoscopy, neither baseline CAC presence nor CAC progression increased the risk of adenoma at follow-up colonoscopy.
The interaction between CAC progression and adenoma at index colonoscopy was signiﬁcant in multivariable model (P= .005). In the
ROC analysis, AUC of CAC progression for adenoma at follow-up colonoscopy was 0.625 (95% CI 0.567–0.684, P< .001) in
participants with adenoma at index colonoscopy.
Participants with CAC progression, who are at high risk of coronary atherosclerosis, may need to be considered for follow-up
evaluation of colorectal adenoma, especially those with adenoma at index colonoscopy.
Abbreviations: BMI = body mass index, BP = blood pressure, CAC = coronary artery calcium, CI = conﬁdence interval, CT =
computed tomography, HR = hazard ratio, HTN = hypertension, MESA = Multi-Ethnic Study of Atherosclerosis.
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Colorectal cancer is a major cause of mortality worldwide.[1]
About 85% of colorectal cancers are considered to develop from
colorectal adenoma though a process termed adenoma-to-
carcinoma sequence.[2] Therefore, early detection and removalEditor: Ismaheel Lawal.
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1of colorectal adenomas is important to prevent their progression
to colon cancer.[3–5] Current guidelines recommend polyp
surveillance based on the histology and number of polyps
detected at baseline examination and family history of colorectal
cancer and high-grade adenomas.[6,7] Presence of adenoma orfrom the corresponding author on reasonable request.
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Lee et al. Medicine (2019) 98:42 Medicineadenoma characteristics at baseline colonoscopy are associated
with the rate of the subsequent adenomas during surveillance.[8]
Compared with the normal group (no adenoma at baseline),
5-year cumulative rates of overall adenoma showed an increase
across the risk groups (adenomas at baseline).[8] Size of adenoma,
number of adenoma or adenoma pathological features at baseline
have been used for risk stratiﬁcation. However, in regards to
other risk factors, there is insufﬁcient evidence to tailor
recommendations. Identiﬁcation of risk factors for colorectal
neoplasia may guide the establishment of strategies targeted
towards colorectal cancer prevention.
Cardiovascular disease is also among the most common causes
of mortality worldwide, and it has enormously contributed to
the economic burdens associated with healthcare costs.[9,10]
Coronary artery calcium (CAC) scanning is an established
method for assessing the presence of atherosclerotic plaque in the
asymptomatic population.[11,12] Current guidelines recommend
that CAC scanning should be considered in the risk assessment of
cardiovascular disease in asymptomatic populations.[13]
Previous studies have indicated the potential relationship
between CAC and colorectal adenoma.[14,15] Colorectal neoplasm
and coronary atherosclerosis have common risk factors, such as
components of metabolic syndrome, diabetes mellitus, smoking,
hyperlipidemia,obesity, andhypertension (HTN).[15–17]However,
only cross-sectional studies have been published to date.[13–15]
Considering the dynamic nature of CAC progression and
colorectal adenoma, a longitudinal analysis of the relationship
between CAC progression and colorectal adenoma or prospective
study are needed. The present study aimed to investigate whether
CAC progression is associated with colorectal adenoma indepen-
dently of other risk factors such as age, sex, smoking, alcohol,
family history of colorectal cancer, body mass index (BMI),
advanced adenomas at index colonoscopy, and baseline presence
of CAC. Interaction test between CAC progression and adenoma
at index colonoscopy was presented for effect modiﬁcation.
2. Methods
2.1. Study populations
We retrospectively reviewed participants who underwent health
screening examinations from July 2006 to November 2017 at a
single health promotion center in South Korea. Medical records
of 781 consecutive participants, who had undergone serial CAC
scans and colonoscopy on the same day during routine health
screening, were reviewed. For this analysis, we excluded 27
subjects with a history of colorectal cancer, colon resection,
inﬂammatory bowel diseases (ulcerative colitis or Crohn’s
disease), or myocardial infarction, in addition to subjects with
a history of previous coronary revascularization. Finally, a total
of 754 subjects were enrolled in the current analysis. The average
duration between computed tomography (CT) evaluations was
3.4±2.5 years. Written informed consent was obtained from
each participant, and the appropriate institutional review board
committee approved the studyprotocol (IRBNo.2018-0188-001).
2.2. Clinical and laboratory data
Participants’ demographics and medical histories were collected
retrospectively through review of medical records. Participants
demographics, including age, sex, height, weight, BMI, and blood
pressure (BP), which were measured at the time of each
evaluation, were collected. Past medical history information2was collected via self-administered medical questionnaire.
Hypertension was deﬁned as a systolic BP of ≥140 mmHg, a
diastolic BP of ≥90 mmHg and/or the current use of antihyper-
tensive agents. Participants with diabetes mellitus were deﬁned as
those with a fasting plasma glucose level of ≥126mg/dL, or
currently on anti-diabetic medications. Smokers were presented
as current smokers and ex-smokers. Laboratory evaluation
included measurements of total cholesterol, triglyceride, low-
density lipoprotein cholesterol, high-density lipoprotein choles-
terol, and fasting glucose levels. Venous blood samples were
collected before 10 AM after 12-hour overnight fasting.2.3. CAC scanning and colonoscopy
Participants underwent CAC scanning using multi-detector CT
(Philips Brilliance 64; Philips Medical Systems, Best, The
Netherlands) using 3-mm slice thickness and 1.5-mm recon-
struction interval. Participants with heart rates >66beats/minute
were administered beta-blockers (25-mg atenolol; Tenormin,
Hyundai, Seoul, Korea) before CT. CAC score was measured
using Agatston method.[18] CAC was repeatedly measured using
multi-detector CT, and progression of CAC was deﬁned
according to Multi-Ethnic Study of Atherosclerosis (MESA)
method. For those with CAC = 0 at baseline, progression was
deﬁned as CAC score >0 at follow-up; for those with 0<CAC
100 at baseline, progression was deﬁned as an annualized change
of ≥10 Agatston units at follow-up; and for those with CAC >
100 at baseline, progression was deﬁned as an annualized percent
change (annualized change in CAC score divided by the baseline
CAC score) of ≥10% at follow-up.[19] Subjects were categorized
as having either CAC progression or CAC non-progression.
Colonoscopies were performed by 6 board-certiﬁed endo-
scopists who had performed a minimum of 3000 colonoscopies
with a cecal intubation rate of 99%. Examinations were
conducted using a standard video colonoscope (CF-H260AI;
Olympus, Tokyo, Japan). The interval duration of follow-up
colonoscopy was recommended by the endoscopists. The size of
adenoma was estimated using biopsy forceps, and in participants
with synchronous adenomas, the largest size obtained was
subject to statistical analysis. The number of adenomas was
calculated from each colonoscopy at every follow-up CT.
Advanced adenomas (adenoma ≥1cm, ≥3 adenomas, and villous
or high-grade adenomas) at index colonoscopy were examined.
All of the adenomas found during colonoscopy were removed
using cold biopsy or standard polypectomy method.
Metachronous adenoma was deﬁned as the presence of any
adenomatous polyps during the follow-up colonoscopy per-
formed at>6months after complete resection of adenoma during
index colonoscopy.[20] In this study, follow-up colonoscopy was
performed at least 1 year after index colonoscopy.2.4. Statistical analysis
According to the presence of adenoma at index colonoscopy,
CAC progression was compared with other potential variables
using independent 2-sample t tests for continuous variables and
chi-squared test or Fisher exact test for categorical variables.
Continuous variables were expressed as the mean± standard
deviation, whereas categorical variables were presented as the
count with proportion. Cox regression analysis was used to
determine the hazard ratio (HR) for the likelihood of
metachronous adenoma at follow-up colonoscopy according
Lee et al. Medicine (2019) 98:42 www.md-journal.comto relevant variables. Adenomas at follow-up colonoscopy were
compared using Kaplan–Meier method, and tested for differences
with log-rank test. Cox regression interaction effect was used to
analyze effect modiﬁcations by interaction tests between CAC
progression and adenoma at index colonoscopy. Prediction was
assessed using a receiver operating characteristic (ROC) curve
and AUC (the area under the curve) was presented. All P values
were 2-sided, and P< .05 was considered statistically signiﬁcant.
All statistical analyses were performed using SAS version 9.2
(SAS Institute Inc., Cary, NC).
3. Results
3.1. Baseline characteristics of the study population
Baseline characteristics of the 754 participants, in terms of the
presence of adenoma at index colonoscopy in comparison to
CAC progression byMESAmethod, are shown in Table 1. Of the
754 participants, 245 (32.5%) had adenoma at index colonos-
copy. Of the 245 participants with adenoma at index
colonoscopy, 95 (38.8%) participants showed CAC progression
at the follow-up CT scan. Of the 509 participants without
adenoma at index colonoscopy, 120 (23.8%) participants
showed CAC progression at the follow-up CT scan. Proportion
of male sex, BMI, HTN, and the proportion of participants with
CAC>0 at baseline were signiﬁcantly higher in participants withTable 1
Baseline characteristics and comparison of baseline characteristics
Multi-Ethnic Study of Atherosclerosis (MESA) method according to p
Without adenoma
CAC non-progression
(n=389)
CAC progre
(n=120
Age, years 50.54±7.59 54.05±8.
Male sex 245 (62.98) 104 (86.6
Smoking, current smoker 18 (4.63) 15 (12.5
Smoking, ex-smoker 34 (8.74) 18 (15.0
Brinkman Index 21.7±9.2 25.6±9.
Alcohol habitual 70 (17.99) 34 (28.3
Family history of colorectal cancer 5 (1.29) 5 (4.17
Aspirin 15 (3.86) 11 (9.17
Body mass index, kg/m2 23.75±2.97 25.08±2.
Systolic blood pressure, mmHg 121.2±15.91 127.5±16
Diastolic blood pressure, mmHg 76.02±10.17 79.81±10
Glucose, mg/dL 96.02±17.95 103.2±22
Total cholesterol, mg/dL 195.5±35.53 195.6±39
Low-density lipoprotein cholesterol, mg/dL 122.9±30.57 124.0±37
High-density lipoprotein cholesterol, mg/dL 52.20±13.55 45.88±10
Log-transformed Triglycerides 2.02±0.22 2.10±0.2
Hypertension 67 (17.22) 40 (33.3
Diabetes mellitus 102 (26.22) 53 (44.1
Lipid medication 100 (25.71) 51 (42.5
CAC at baseline, mean 14.06±83.12 53.16±11
CAC >0 at baseline 65 (16.71) 57 (47.5
Advanced adenoma at index colonoscopy
Adenoma ≥1 cm
3 or more adenomas
Villous or high-grade adenoma
2 or more follow-up of colonoscopy during
CAC scan follow-up
117 (30.08) 51 (42.5
CAC scan follow-up duration 48.79±25.16 55.54±26
Data are presented as mean ± SD (standard deviation) or number (%).
CAC= coronary artery calcium.
3CAC progression, regardless of adenoma status at index
colonoscopy.3.2. Risk factors for metachronous adenoma at follow-up
colonoscopy according to CAC progression
The risk factors for metachronous adenoma at follow-up
colonoscopy are summarized in Table 2. In univariable analysis
of participants without adenoma at index colonoscopy, the risk
factors for metachronous adenoma at follow-up colonoscopy
were as follows: age (HR=1.034, 95% CI 1.015–1.054,
P= .001), male sex (HR=2.443, 95% CI 1.687–3.539,
P< .01), HTN (HR=1.584, 95% CI 1.021–2.459, P= .04),
and CAC >0 at baseline (HR=1.84, 95% CI 1.209–2.798,
P= .004). In multivariable analysis, age (HR=1.046, 95% CI
1.019–1.075, P= .001), male sex (HR=2.803, 95% CI 1.697–
4.630, P< .01), and BMI (HR=1.046, 95% CI 1.019–1.075,
P= .001) were signiﬁcant risk factors for metachronous
adenoma at follow-up colonoscopy in participants without
adenoma at index colonoscopy. Neither the presence of CAC
nor CAC progression increased the risk of metachronous
adenoma at follow-up colonoscopy in participants without
adenoma at index colonoscopy.
Effect modiﬁcation by interaction tests between adenoma at
index colonoscopy and CAC progression in univariable andbetween subjects who CAC progression and non-progression by
resence of adenoma at index colonoscopy.
With adenoma
ssion
) P value
CAC non-progression
(n=150)
CAC progression
(n=95) P value
17 <.001 54.38±7.93 56.08±7.67 .09
7) <.001 110 (73.33) 85 (89.47) .002
0) .002 18 (12.00) 11 (11.58) .92
) 20 (13.33) 22 (23.16)
9 25.4±11.5 22.8±9.6
3) .14 45 (30.00) 34 (35.79) .34
) .06 1 (0.67) 1 (1.05) .99
) .021 10 (6.67) 11 (11.58) .18
58 <.001 24.21±2.56 25.22±3.03 .006
.10 .0002 127.42±16.92 130.0±16.55 .23
.41 .0004 79.85±10.16 80.96±8.81 .37
.60 .002 98.90±18.48 102.8±18.04 .10
.02 .96 194.52±36.38 199.8±39.36 .27
.75 .78 122.40±34.15 127.8±37.19 .25
.47 <.001 48.64±12.24 48.51±10.68 .93
4 <.001 2.06±0.22 2.05±0.20 .88
3) .0002 44 (29.33) 41 (43.16) .027
7) .0002 52 (34.67) 39 (41.05) .31
0) .0004 51 (34.00) 30 (31.58) .69
3.5 .0006 55.71±294.3 71.88±225.3 .62
0) <.001 46 (30.67) 56 (58.95) <.001
33 (22.00) 22 (23.16) .83
17 (11.33) 10 (10.53) .84
28 (18.67) 14 (14.74) .42
7 (4.67) 5 (5.26) .99
0) .011 53 (35.33) 45 (47.37) .06
.68 .012 45.73±22.11 47.28±22.04 .59
Table 2
Univariable and multivariable cox regression for colonic adenoma at follow-up colonoscopy by presence of adenoma at index
colonoscopy.
Univariable model Multivariable model I Multivariable model II
HR (95% CI) P value HR (95% CI) P value HR (95%CI) P value
Without adenoma
Age, year 1.034 (1.015–1.054) .001 1.046 (1.019–1.075) .001
Male 2.443 (1.687–3.539) <.001 2.803 (1.697–4.630) <.001
Smoking, current 0.638 (0.281–1.447) .28 0.519 (0.205–1.318) .16
Alcohol habitual 1.049 (0.665–1.657) .83 1.042 (0.608–1.786) .88
Family history of colorectal cancer 3.149 (0.876–11.31) .07 2.786 (0.721–10.77) .13
Body mass index 1.043 (0.979–1.111) .19 1.046 (1.019–1.075) .001
Hypertension 1.584 (1.021–2.459) .04
Diabetes mellitus 1.458 (0.982–2.164) .06
Lipid medication 1.425 (0.957–2.121) .08
CAC >0 at baseline (vs CAC=0) 1.840 (1.209–2.798) .004 1.285 (0.796–2.077) .30
CAC progression (vs CAC non-progression) 1.252 (0.816–1.922) .30 0.832 (0.514–1.347) .45
With adenoma
Age, year 1.017 (0.985–1.051) .30 1.009 (0.972–1.048) .64 1.007 (0.969–1.047) .72
Male 2.507 (1.327–4.734) .005 2.495 (1.212–5.138) .013 2.575 (1.223–5.421) .013
Smoking, current 0.879 (0.403–1.918) .74 1.509 (0.589–3.865) .39 1.612 (0.614–4.228) .33
Alcohol habitual 0.553 (0.321–0.950) .032 0.374 (0.191–0.731) .004 0.357 (0.180–0.709) .003
Family history of colorectal cancer 0.723 (0.045–11.70) .81 0.663 (0.024–18.61) .81 0.743 (0.026–21.52) .86
Body mass index 1.076 (0.979–1.182) .12 1.017 (0.915–1.130) .75 1.003 (0.901–1.115) .96
Hypertension 0.786 (0.462–1.337) .37
Diabetes mellitus 1.265 (0.746–2.147) .38
Lipid medication 0.931 (0.543–1.595) .79
Adenoma ≥1 cm 0.896 (0.400–2.004) .78 0.503 (0.162–1.558) .23
3 or more adenomas 2.336 (1.113–4.902) .025 2.600 (1.156–5.849) .021
Villous or high-grade adenoma 0.677 (0.198–2.311) .53 0.421 (0.082–2.164) .30
CAC >0 at baseline (vs CAC=0) 2.005 (1.182–3.402) .01 1.436 (0.788–2.618) .23 1.398 (0.761–2.568) .27
CAC progression (vs CAC non-progression) 3.033 (1.736–5.299) <.001 2.582 (1.405–4.746) .002 2.739 (1.478–5.077) .001
CAC= coronary artery calcium, CI= conﬁdence interval, HR=hazard ratio.
Univariable model=Adenoma at index colonoscopy ∗ CAC progression interaction test P value= .0137.
Multivariable model 1=Adenoma at index colonoscopy ∗ CAC progression interaction test P value= .0054.
Lee et al. Medicine (2019) 98:42 Medicinemultivariable models were statistically signiﬁcant (univariable
model, P= .014; multivariable model, P= .005).
In participants with adenoma at index colonoscopy, risk
factors for metachronous adenoma at follow-up colonoscopy
were male sex (HR=2.507, 95% CI 1.327–4.734, P= .005), ≥3
adenomas at the index colonoscopy (HR=2.336, 95%CI 1.113–
4.902, P= .025), CAC >0 at baseline (compared to CAC=0)
(HR=2.005, 95% CI 1.182–3.402, P= .01), and CAC progres-
sion (HR=3.033, 95% CI 1.736–5.299, P< .01). Multivariable
analysis (multivariable model I) showed that the risks of
metachronous adenoma were signiﬁcantly higher in men (HR
=2.495, 95% CI 1.212–5.138, P= .013) and those with CAC
progression (HR=2.582, 95% CI 1.405–4.746, P= .002).
Multivariable analysis considering adenoma characteristics at
index colonoscopy (multivariable model II) showed that male sex
(HR=2.575, 95% CI 1.223–5.421, P= .013), ≥3 adenomas at
index colonoscopy (HR=2.60, 95% CI 1.156–5.849, P= .021),
and CAC progression (HR=2.739, 95% CI 1.478–5.077,
P= .001) increased the risks of adenoma.
Kaplan–Meier cumulative event curve for metachronous
adenoma at follow-up colonoscopy between CAC progression
and CAC non-progression groups is shown in Figure 1. CAC
progression increased the risk of adenoma at follow-up
colonoscopy in participants with adenoma at index colonoscopy
(HR=1.497, 95% CI 1.059–2.064, log-rank test P= .021), but
not in participants without adenoma at index colonoscopy
(HR= .932, 95% CI 0.66–1.317, log-rank test P= .69).4In the ROC analysis, AUC of CAC progression for adenoma at
follow-up colonoscopy was 0.625 (95% CI 0.567–0.684,
P< .001) in participants with adenoma at index colonoscopy
(Fig. 2). CAC progression was not signiﬁcant in participants
without adenoma (AUC=0.521, 95% CI 0.481–0.561, P
= .314).
4. Discussion
In this study, we investigated the relationship between CAC
progression and metachronous colorectal adenoma in a popula-
tion of asymptomatic healthy Koreans who underwent serial
health check-ups. Progression of CAC is associated with
metachronous adenoma in participants with adenoma at index
colonoscopy, but not in those without adenoma at index
colonoscopy. Interaction test between the progression of CAC
and adenoma at index colonoscopy was statistically signiﬁcant
after adjusting for other confounders.
Previous studies have indicated potential relationships between
CAC and colorectal adenoma. Choi et al showed that the
prevalence of advanced adenoma is higher in subjects with severe
coronary atherosclerosis.[13] Yun et al reported that colorectal
adenomawasmore likely to be present in participants with higher
CAC.[21] The ﬁndings of the present study expand on these
previous results by demonstrating serial assessment by CAC
scans and colonoscopy. A recent study has indicated that CAC
progression is related to incident hard and total coronary heart
Figure 1. Kaplan–Meier curves demonstrating cumulative incidence of metachronous adenoma at follow-up colonoscopy in participants without adenoma at
index colonoscopy (A) and in participants with adenoma at index colonoscopy (B).
Lee et al. Medicine (2019) 98:42 www.md-journal.comdisease events in a multiethnic cohort with CAC scans performed
an average of 2.5 years apart.[19] The progression of CAC adds a
signiﬁcant incremental predictive value for all-cause mortality
after adjusting for time between scans, demographics, risk
factors, and baseline CAC score.[22] In addition to previous
ﬁndings, our results have demonstrated that progression of CAC
increased the risk of metachronous adenoma. The threshold of
CAC increase or change optimal cut-off point was 17.38
(sensitivity=37.22 (95% CI 31.8–42.9), speciﬁcity=84.27
(95% CI 80.5–87.5)) (supplementary Figure 1, http://links.
lww.com/MD/D297). In all participants, AUC by progression
score of CAC for adenoma at follow-up colonoscopy was 0.604
(95% CI 0.568–0.641, P< .001). In ROC analysis, CAC
progression was signiﬁcant in participants with adenoma at
index colonoscopy. To our knowledge, this is the ﬁrst study to
reveal the longitudinal relationship between progression of CAC
and colorectal adenoma. Given the heterogeneous nature of the
development of colorectal adenoma and progression of CAC,
serial assessment by CT scans may be helpful to identify
participants with high risk of colorectal adenoma at follow-up.
Participants with CAC progression are considered to be at high
risk of coronary atherosclerosis. The traditional CAC scoresFigure 2. Receiver operating characteristic curve of coronary artery calcium progr
without adenoma at index colonoscopy (A) and participants with adenoma at in
calcium, CI=conﬁdence interval, ROC curve= receiver operating characteristic c
5make several assumptions about the biology of calciﬁcation and
atherosclerosis that warrant discussion.[23] An improved or
advanced CAC score will provide an opportunity to reconsider
assumptions inherent in traditional CAC scoring.[23] However,
CAC has a signiﬁcant prognostic value across a wide spectrum of
age and risk factor proﬁles. CAC is associated with atheroscle-
rotic burden, and CAC scanning has been proposed as a measure
to track coronary heart disease progression and the effects of risk
factor modiﬁcation on atherosclerosis.[22] Despite some debates
about the relationship between CAC and atherosclerosis, CAC
and its progression are markers of subclinical atherosclerosis.[24]
Repeat CAC scanning has been proposed as a method to track
progression of total atherosclerosis burden and CAC progression
correlates with worsening atherosclerosis.[25]
In previous cross-sectional study, prevalence of colorectal
adenoma was greater in subjects with mild or signiﬁcant CAD
and the presence of advanced colorectal adenoma was
signiﬁcantly associated with signiﬁcant CAD.[13] This study
supports previous ﬁndings and presented the association between
CAC and colorectal adenoma in longitudinal analysis. These are
helpful for planning the screening of colorectal neoplasm and
coronary atherosclerosis in asymptomatic individuals. But we didession prediction model for adenoma at follow-up colonoscopy in participants
dex colonoscopy (B). AUC= the area under the curve, CAC=coronary artery
urve.
Lee et al. Medicine (2019) 98:42 Medicinenot identify the association between CAC with advanced
adenoma at follow-up colonoscopy, the association between
progression of CAC and advanced adenoma is needed to clarify
in the future.
There are possible explanations for the current relationship
between progression of CAC and colorectal adenoma. The
progression of CAC and colorectal adenoma may be associated,
probably through insulin resistance or inﬂammation. Several
previous studies have reported that metabolic syndrome was a
risk factor for colorectal neoplasm and also atherosclerosis.[26,27]
Insulin resistance is believed to play amajor role in the underlying
pathophysiology ofmetabolic syndrome, possibly contributing to
atherosclerosis[28] and colorectal adenoma.[29] Since metabolic
syndrome has a positive relationship with colorectal cancer,[16]
progression of CAC representing atherosclerosis and adenoma
representing colorectal neoplasia may have shared risk factors.
The insulin/insulin-like growth factor-1 pathway was suggested
by mediating mitogenicity by activation of K-ras, increasing the
activity of ras protein occurring in abnormal colonocytes, and
stimulating the progression of adenomas into cancers.[16]
Otherwise, several inﬂammatory biomarkers, such as macro-
phage inhibitory cytokine 1 or pro-inﬂammatory cytokine
macrophage migration inhibitory factor (MIF)[30–32] and high-
sensitivity C-reactive protein (hs-CRP),[33,34] have been associat-
ed with increased risks of cardiovascular disease and colorectal
cancer. In addition, sub-clinical inﬂammation induces oxidative
stress progresses the development of atherosclerotic lesions and
also leads to DNA damage with an increased risk of developing
colorectal cancer.[35] CAC progression in participants with
adenoma at index colonoscopy may have a higher risk for insulin
resistance or inﬂammation. Given that there was no deﬁnite
serologic marker for advanced adenoma or adenoma, ﬁnding
inﬂammatory candidates for colorectal neoplasm may be helpful
in applying individualized colonoscopy intervals in clinical
practice.
There were several limitations to this study. Given the
retrospective nature of the current study, predominance of male
participants (71.9%), self- referred, and relatively small sample
size, the study cohort did not represent the general population.
Furthermore, the study may contain selection bias, and
confounding factors to infer causal relationships between
colorectal adenoma and CAC progression were limited. We
did not include inﬂammatory biomarkers (MIF, TNF-a, IL-6 or
hs-CRP) or insulin resistance markers. In this study, any alcohol
consumption seemed to lower the risk of adenoma in multivari-
able models. We did not identify the frequency of alcohol
consumption, drinking pattern, and whether participants drank
strong alcohol.More information related to alcohol consumption
is needed to clarify these ﬁndings. CAC scans and colonoscopy
evaluation intervals were inconsistent. We did not identify the
association between CAC with advanced adenoma at follow-up
colonoscopy. However, the longitudinal data showed that
participants with CAC progression were at risk of metachronous
adenoma at follow-up colonoscopy. The interaction test between
CAC progression and adenoma also showed statistical signiﬁ-
cance in multivariable analysis. By demonstrating the relation-
ship between metachronous colorectal adenoma and CAC
progression, serial CAC evaluation in participants who were
screened for cardiac disease may be helpful in predicting the risk
of colorectal adenoma.
In conclusion, CAC progression is associated with metachro-
nous adenoma at follow-up colonoscopy in participants with6adenoma at index colonoscopy. Individuals with CAC progres-
sion, who are at high risks of coronary atherosclerosis, may need
to be considered for follow-up evaluation of colorectal adenoma,
especially those with adenoma at previous colonoscopy.
Assessment according to individual risk status is needed for
colorectal neoplasm, and this study may help physicians to better
understand the relationship between CAC progression and
colorectal adenoma. Prospective study and investigation in
different ethnic populations and explorations of genetic aspects
will help clarify the risks of colorectal neoplasm. Further
prospectively designed studies conﬁrming the relationship
between CAC progression and colorectal adenoma are war-
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